ESMO 2020 Highlights Podcast

 

1. Nivolumab-cabozantinib doublet is effective as first-line treatment in advanced RCC
   Choueiri TK, et al. ESMO 2020 Virtual Meeting, abstract 696O.


2. Trials with chemoimmunotherapy in metastatic TNBC show contradicting results
   Emens LA, et al. ESMO 2020 Virtual Meeting, abstract LBA16; Miles DW, et al. ESMO 2020 Virtual Meeting, abstract LBA15.


3. Adjuvant osimertinib in NSCLC reduces risk of CNS recurrence
   Tsuboi M, et al. ESMO 2020 Virtual Meeting, abstract LBA1.


4. CDK4/6 inhibitor palbociclib effective in ER+ advanced endometrial cancer
   Mirza MR, et al. ESMO 2020 Virtual Meeting, abstract LBA28.


5. Nivolumab plus chemotherapy: new standard for first-line treatment of gastric cancer?
   Möhler M, et al. ESMO 2020 Virtual Meeting, abstract LBA6; Boku N, et al. ESMO 2020 Virtual Meeting, abstract LBA7.


6. Lorlatinib outperforms crizotinib in ALK-positive advanced NSCLC
   Solomon B, et al. ESMO 2020 Virtual Meeting, abstract LBA2.

Posted on 23 September, 202022 December, 2020